ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD.

Years

Shop

Shop
All

Favorites

You are here: Home > Suppliers > ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD. > Company Profile

Basic Information

Company Name

ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD.

Year of Establishment

1956

Enterprise Size

more than 1000

Company Introduction

Founded in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. was listed on the A-share market in 2000 and is a state-owned listed company. After more than 60 years of development, Hisun Pharmaceuticals has become a comprehensive pharmaceutical enterprise group integrating the whole value chain of research, production and marketing, as well as the vertical integration of APIs and preparations. The company focuses on multi-industry development of chemical drugs, biopharmaceuticals, animal drugs, traditional Chinese medicines and commercial distribution, accelerates the layout of emerging markets such as the health industry and health aesthetics, and has been selected as one of China's top 500 manufacturing enterprises and one of China's top 100 pharmaceutical industry enterprises for many times, and has been awarded the honors of National Model Enterprise for Technological Innovation, National May 1st Labor Award, and Quality Award of the Zhejiang Provincial Government, and other honors and titles. As one of the first batch of innovative enterprises in China, Hisun Pharmaceutical has a high-level and multi-dimensional R&D platform, with R&D centers in Taizhou, Shanghai, Hangzhou, the U.S.A. and other places, and first-class R&D platforms such as a national enterprise technology center, the first batch of postdoctoral research stations in Zhejiang Province that are qualified to independently recruit post-doctoral students, and a provincial key laboratory in Zhejiang Province, which has a full-chain of drug research and development capability. 2021 the company In 2021, the company's first self-developed innovative drug, Habermeb Tablet, was approved and listed on the market, which is the only Class 1 new drug approved in the domestic cardiovascular field in recent years, and was selected in the "14th Healthy China Annual Forum-Top 10 New Drugs (Domestic) List". In terms of biopharmaceuticals, we have established a rich product pipeline in autoimmune and tumor therapeutic areas, with 5 products approved for marketing, more than 10 products in clinical trials, and a number of products in preclinical studies, and the first insulin product, Mentholatum, has been approved and won the national procurement bid. In recent years, the company has undertaken more than 50 special projects for the creation and manufacture of major new drugs, won more than 10 scientific and technological progress awards at the provincial and ministerial levels, applied for more than 1,100 patents, obtained more than 500 authorized patents, and six invention patents have won the "China Patent Award of Excellence", etc. The company has been awarded the "China Patent Award of Excellence" by the Ministry of Commerce of the People's Republic of China. With the spirit of craftsmanship, Hisun Pharmaceuticals is the first to create QEHS management system in China, and its products have passed the inspection of the global pharmaceutical quality standard system. Hisun Pharmaceuticals has introduced high-precision equipments from home and abroad, and has built more than 80 international first-class and advanced production lines for preparation, which are under online automatic control throughout the whole process. As the first local pharmaceutical enterprise to realize localized production of original research drugs in China, Hisun has a leading CSO platform with advanced pharmaceutical foundation in China, which constitutes a new marketing mode based on specialized academic promotion under the compliance system, online and offline digital intelligent three-dimensional marketing, customized R&D and production by global pharmaceutical enterprises, and support for the synergistic development of innovative pharmaceutical enterprises. The company's international sales network covers more than 70 countries and regions around the world, the scale of domestic hospital admissions of medicines exceeds 10,000, more than 40 specifications have passed or are deemed to have passed the consistency evaluation, and more than 10 kinds of medicines have been selected for the national collection and procurement, which significantly reduces the cost of medicines for patients. As a state-owned enterprise with a sense of responsibility and mission, Hisun actively undertakes the major strategic needs of the country, and products such as Tamiflu, anti-Ebola drugs, anti-super-resistant bacteria tigecycline, and anti-tuberculosis drug cycloserine have helped patients in many countries, which demonstrates the responsibility and commitment of Hisun as a national pharmaceutical enterprise. During the epidemic, the company's faviravir tablets were quickly approved and listed on the market, and rushed to the world to help fight the epidemic, and successively received a number of thank-you letters from the State Council's Joint Prevention and Control Group, the Ministry of Science and Technology of the People's Republic of China and Zhejiang Provincial Medical Supplies Protection Group, which was praised as the well-deserved "arsenal" for the fight against the epidemic. More than 60 years of development history has accumulated the deep heritage of Hisun brand. Hisun Pharmaceutical will take patients' needs as the guide, take the refined management system as the foundation, take the integrated operation of research, production and marketing as the skeleton, take the specialized talent echelon as the energy, and take continuous pragmatic innovation as the driving force to deliver world-class quality, show the new face of Hisun and make efforts to build a new brand of national conscientious pharmaceuticals.

Main Competitive Advantages

Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,

Postal Code

318000

Website

http://www.hisunpharm.com

Other Competitive Advantages

"First batch of innovative enterprises"、"National technology innovation demonstration enterprises"、"National Industrial Brand Demonstration Enterprise of the Chinese Ministry of Industry and Information Technology"、“Top Domestic Industrial Manufacturing 500”、“China's top 100 pharmaceutical enterprises"、"Top 100 pharmaceutical international enterprises"、“China's innovative pharmaceutical companies"、“China's top 100 drug research and development"

Milestone

In 1956, Haimen Chemical Factory was established, starting from the village chemical industry; in 1976, the name was changed to Haimen Pharmaceutical Factory, entering the field of pharmaceuticals; in 1997, the whole company was reorganized to become a wholly state-owned company--Zhejiang Hisun Group Co. In 1998, the group company initiated the establishment of Zhejiang Hisun Pharmaceutical Co., Ltd. together with seven domestic and foreign organizations. 2000 Hisun Pharmaceutical issued 40 million A shares, which were listed on the Shanghai Stock Exchange. 2009 Hisun Pharmaceutical and Xellia Hong Kong Ltd. established a joint venture subsidiary, Xellia (Taizhou) Pharmaceutical Ltd. 2010 Hisun Pharmaceutical (USA) Ltd. was founded in the United States. Pharmaceuticals (U.S.A.) Ltd. was established in Princeton, New Jersey, U.S.A. In 2012, Hisun Pharmaceuticals Ltd. was established, which was renamed as Hisun Pharmaceuticals in 2018, and is 100% owned by Hisun in 2021. 2015 Hisun Pharmaceuticals Nantong Co. Ltd. was established. 2018 Zhejiang Haisheng Pharmaceuticals Ltd. was established. 2019 Zhejiang Bioray Pharmaceuticals Ltd. was established. Ltd. was established in 2020. 2022 Hisun (Hainan) Medical Technology Development Co., Ltd.

Trading Ability

Business type

Manufacturer

Main Sales Market

North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa,

R&D Capacity

OEM,ODM,Own Brand,

Contract Customization

CMO,CDMO,